Treatment of alopecia totalis with a combination of inosine pranobex and diphencyprone compared to each treatment alone.
Recent developments in alopecia areata have included the use of oral inosine pranobex and the introduction of diphencyprone as a contact sensitizer. Good results have been claimed for these treatments even in severe forms of the disease. We performed a study to investigate the efficacy of a combination of these treatments in the most severe form of alopecia areata. Thirty-three patients suffering from alopecia totalis were enrolled. Subjects were divided into three groups matched for age and sex. One group received treatment with inosine pranobex (50 mg/kg/day) for 6 months. The second was sensitized to diphencyprone and treated for 6 months by maintenance of contact allergic dermatitis on the scalp. The third received both treatments. There was no evidence of response to inosine pranobex in any of the 22 subjects who received this treatment. Only two of 22 patients responded to diphencyprone. Patients with long-standing alopecia totalis contemplating diphencyprone therapy should be advised that the chances of success are only around 10%. Inosine pranobex does not appear to improve the response rate.
Berth-Jones
J
J
Department of Dermatology, Leicester Royal Infirmary, UK.
Hutchinson
P E
PE
D000293:Adolescent; D000328:Adult; D000368:Aged; D000505:Alopecia / Q000188:drug therapy*; D003521:Cyclopropanes / Q000627:therapeutic use*; D003877:Dermatitis, Contact / Q000209:etiology / Q000503:physiopathology; D004359:Drug Therapy, Combination; D005260:Female; D006197:Hair / Q000254:growth & development; D006801:Humans; D007542:Inosine Pranobex / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged
D003521:Cyclopropanes; C029402:diphenylcyclopropenone; D007542:Inosine Pranobex